# iRhythm Technologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/irhythm-technologies

- Industry: Medical Devices & Equipment
- Headquarters: San Francisco, US
- Website: www.irhythmtech.com
- Total disclosed funding: $85M
- Latest round: Series E (May 22, 2014)
- Investors on record: 9

## About

iRhythm Technologies Inc. specializes in innovative cardiac monitoring solutions that enhance patient care through advanced technology, providing continuous and accurate data for arrhythmia detection and management.Founded in 2006, iRhythm Technologies Inc. is headquartered in San Francisco, US, and focuses on delivering cardiac monitoring solutions. The company went public in October 2016, raising USD 107 mn in an IPO. The CEO is Quentin Blackford, who has led the company through its growth and recent public offering.iRhythm Technologies, Inc. specializes in cardiac monitoring solutions, primarily through its flagship product, the Zio® ECG monitor. This advanced technology offers continuous and accurate cardiac monitoring for patients experiencing arrhythmias. The Zio ECG monitors are designed for comfort and ease of wear, thereby improving patient compliance. The service provides an end-to-end solution including data collection, comprehensive reports, and diagnostic support, allowing healthcare providers to make informed decisions. iRhythm serves healthcare professionals, hospitals, and clinics in the United States, leveraging extensive heartbeat data analysis from over 8 million patients and 1.5 billion hours of curated data.For the most recent fiscal year in 2024, iRhythm reported revenue of USD 591.84 mn, with an EBITDA of USD -94.79 mn. The company's revenue model relies on a subscription-based service for cardiac monitoring, collaborating directly with healthcare providers to streamline patient monitoring and data interpretation, supported by FDA-cleared technology and AI-driven analytics.Looking ahead, iRhythm Technologies Inc. aims to expand its product line and geographic reach. The company is exploring new product offerings designed to enhance cardiac monitoring capabilities, with a focus on launching these innovations in the near future. Additionally, iRhythm plans to expand its presence in international markets, though specific regions and timelines have yet to be detailed. The funds raised from the USD 107 mn IPO in October 2016 are expected to support these growth initiatives, allowing for investment in new technologies and market expansion.

## Funding rounds

- Series E, May 22, 2014, $17M — Norwest Venture Partners, Novo Holdings
- Series D, Apr 1, 2013, $16M — Norwest Venture Partners, New Leaf Venture Partners, Synergy Life Science Partners, Kaiser Permanente Ventures
- Series C, Jan 25, 2012, $12M — Mohr Davidow Ventures, New Leaf Venture Partners, Synergy Life Science Partners, Kaiser Permanente Ventures
- Series C, Oct 17, 2011, $3.3M — Kaiser Permanente Ventures
- Series C, May 2, 2011, $6.7M — Mohr Davidow Ventures, New Leaf Venture Partners, Synergy Life Science Partners, St. Jude Medical, Stanford University
- Series B, May 13, 2010, $10M — Mohr Davidow Ventures, Synergy Life Science Partners, St. Jude Medical
- Series A, Apr 10, 2009, $6.5M — Mohr Davidow Ventures, Synergy Life Science Partners, UNC Kenan-Flagler Private Equity Fund, Stanford University
- Series A, May 15, 2008, $9.7M — Mohr Davidow Ventures, Synergy Life Science Partners
- Series A, Jan 25, 2007, $3M — Mohr Davidow Ventures, Synergy Life Science Partners

## Investors

- Mohr Davidow Ventures (https://capitalatlas.ai/funds/mohr-davidow-ventures) — Series A, Series B, Series C
- Synergy Life Science Partners (https://capitalatlas.ai/funds/synergy-life-science-partners) — Series A, Series B, Series C, Series D
- UNC Kenan-Flagler Private Equity Fund (https://capitalatlas.ai/funds/unc-kenan-flagler-private-equity-fund) — Series A
- Stanford University — Series A, Series C
- St. Jude Medical — Series B, Series C
- New Leaf Venture Partners (https://capitalatlas.ai/funds/new-leaf-venture-partners) — Series C, Series D
- Kaiser Permanente Ventures (https://capitalatlas.ai/funds/kaiser-permanente-ventures) — Series C, Series D
- Norwest Venture Partners (https://capitalatlas.ai/funds/norwest-venture-partners) — Series D, Series E
- Novo Holdings — Series E